Inhibition of SETMAR-H3K36me2-NHEJ repair axis in residual disease cells prevents glioblastoma recurrence.
NHEJ
SETMAR
glioblastoma
radiation resistance
residual disease
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
18 12 2020
18 12 2020
Historique:
pubmed:
28
5
2020
medline:
29
4
2021
entrez:
28
5
2020
Statut:
ppublish
Résumé
Residual disease of glioblastoma (GBM) causes recurrence. However, targeting residual cells has failed, due to their inaccessibility and our lack of understanding of their survival mechanisms to radiation therapy. Here we deciphered a residual cell-specific survival mechanism essential for GBM relapse. Therapy resistant residual (RR) cells were captured from primary patient samples and cell line models mimicking clinical scenario of radiation resistance. Molecular signaling of resistance in RR cells was identified using RNA sequencing, genetic and pharmacological perturbations, overexpression systems, and molecular and biochemical assays. Findings were validated in patient samples and an orthotopic mouse model. RR cells form more aggressive tumors than the parental cells in an orthotopic mouse model. Upon radiation-induced damage, RR cells preferentially activated a nonhomologous end joining (NHEJ) repair pathway, upregulating Ku80 and Artemis while downregulating meiotic recombination 11 (Mre11) at protein but not RNA levels. Mechanistically, RR cells upregulate the Su(var)3-9/enhancer-of-zeste/trithorax (SET) domain and mariner transposase fusion gene (SETMAR), mediating high levels of H3K36me2 and global euchromatization. High H3K36me2 leads to efficiently recruiting NHEJ proteins. Conditional knockdown of SETMAR in RR cells induced irreversible senescence partly mediated by reduced H3K36me2. RR cells expressing mutant H3K36A could not retain Ku80 at double-strand breaks, thus compromising NHEJ repair, leading to apoptosis and abrogation of tumorigenicity in vitro and in vivo. Pharmacological inhibition of the NHEJ pathway phenocopied H3K36 mutation effect, confirming dependency of RR cells on the NHEJ pathway for their survival. We demonstrate that the SETMAR-NHEJ regulatory axis is essential for the survival of clinically relevant radiation RR cells, abrogation of which prevents recurrence in GBM.
Sections du résumé
BACKGROUND
Residual disease of glioblastoma (GBM) causes recurrence. However, targeting residual cells has failed, due to their inaccessibility and our lack of understanding of their survival mechanisms to radiation therapy. Here we deciphered a residual cell-specific survival mechanism essential for GBM relapse.
METHODS
Therapy resistant residual (RR) cells were captured from primary patient samples and cell line models mimicking clinical scenario of radiation resistance. Molecular signaling of resistance in RR cells was identified using RNA sequencing, genetic and pharmacological perturbations, overexpression systems, and molecular and biochemical assays. Findings were validated in patient samples and an orthotopic mouse model.
RESULTS
RR cells form more aggressive tumors than the parental cells in an orthotopic mouse model. Upon radiation-induced damage, RR cells preferentially activated a nonhomologous end joining (NHEJ) repair pathway, upregulating Ku80 and Artemis while downregulating meiotic recombination 11 (Mre11) at protein but not RNA levels. Mechanistically, RR cells upregulate the Su(var)3-9/enhancer-of-zeste/trithorax (SET) domain and mariner transposase fusion gene (SETMAR), mediating high levels of H3K36me2 and global euchromatization. High H3K36me2 leads to efficiently recruiting NHEJ proteins. Conditional knockdown of SETMAR in RR cells induced irreversible senescence partly mediated by reduced H3K36me2. RR cells expressing mutant H3K36A could not retain Ku80 at double-strand breaks, thus compromising NHEJ repair, leading to apoptosis and abrogation of tumorigenicity in vitro and in vivo. Pharmacological inhibition of the NHEJ pathway phenocopied H3K36 mutation effect, confirming dependency of RR cells on the NHEJ pathway for their survival.
CONCLUSIONS
We demonstrate that the SETMAR-NHEJ regulatory axis is essential for the survival of clinically relevant radiation RR cells, abrogation of which prevents recurrence in GBM.
Identifiants
pubmed: 32458986
pii: 5847629
doi: 10.1093/neuonc/noaa128
pmc: PMC7746947
doi:
Substances chimiques
Histone-Lysine N-Methyltransferase
EC 2.1.1.43
SETMAR protein, human
EC 2.1.1.43
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1785-1796Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Essays Biochem. 2012;52:93-111
pubmed: 22708566
Mol Cancer Res. 2015 Feb;13(2):293-304
pubmed: 25280969
Annu Rev Biochem. 2008;77:229-57
pubmed: 18275380
Eur J Cancer. 1999 Jan;35(1):111-6
pubmed: 10211098
J Cell Biol. 2006 Mar 13;172(6):823-34
pubmed: 16520385
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):540-5
pubmed: 21187428
DNA Repair (Amst). 2004 Aug-Sep;3(8-9):909-18
pubmed: 15279776
Onco Targets Ther. 2019 Nov 25;12:10139-10151
pubmed: 31819508
PLoS One. 2009;4(4):e5323
pubmed: 19390626
Mol Pharmacol. 1999 Jul;56(1):141-6
pubmed: 10385694
Br J Cancer. 2009 Sep 1;101(5):816-21
pubmed: 19672258
Carcinogenesis. 2015 Jun;36(6):685-95
pubmed: 25863126
Annu Rev Biochem. 2010;79:181-211
pubmed: 20192759
Cold Spring Harb Perspect Biol. 2014 Aug 07;6(9):a016428
pubmed: 25104768
Mol Cell. 2014 Jan 9;53(1):49-62
pubmed: 24289921
Radiat Res. 2013 Apr;179(4):383-92
pubmed: 23373901
J Natl Cancer Inst. 2005 May 18;97(10):765-77
pubmed: 15900046
Neurol Sci. 2013 Aug;34(8):1421-8
pubmed: 23224642
Chem Biol. 2015 Jan 22;22(1):17-29
pubmed: 25579208
Cell Oncol (Dordr). 2019 Feb;42(1):107-116
pubmed: 30361826
Int J Cancer. 2018 May 15;142(10):2175-2185
pubmed: 29297932
Mol Cell. 2012 Aug 24;47(4):497-510
pubmed: 22920291
PLoS Genet. 2010 Aug 26;6(8):
pubmed: 20865123
Nat Rev Genet. 2012 Jan 18;13(2):123-34
pubmed: 22251873
Sci Rep. 2016 May 25;6:26538
pubmed: 27221528
Oncogene. 2001 Feb 8;20(6):739-47
pubmed: 11314007
PLoS Genet. 2009 Mar;5(3):e1000435
pubmed: 19325889
Nat Rev Genet. 2012 Jan 04;13(2):97-109
pubmed: 22215131
Cancer Res. 2010 Nov 15;70(22):9243-52
pubmed: 20935218
J Vis Exp. 2010 Sep 08;(43):
pubmed: 20864925
BMC Cancer. 2017 May 19;17(1):344
pubmed: 28526069
Mol Cell. 2011 Nov 18;44(4):609-20
pubmed: 22099308
Genes Dev. 2011 Jul 1;25(13):1345-58
pubmed: 21724828
J Cell Biol. 2017 Jul 3;216(7):1959-1974
pubmed: 28572115
J Cell Biol. 2007 Sep 24;178(7):1101-8
pubmed: 17893239
Oncotarget. 2018 Jun 12;9(45):27667-27681
pubmed: 29963228
Cancer Sci. 2003 Oct;94(10):894-900
pubmed: 14556663
Blood. 2009 Aug 27;114(9):1852-8
pubmed: 19458360
EMBO J. 2019 Oct 1;38(19):e96659
pubmed: 31454099